{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:17:49Z","timestamp":1790727469080,"version":"4.1.0"},"reference-count":202,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T00:00:00Z","timestamp":1559865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008886","name":"Princess Takamatsu Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012045","name":"Kawano Masanori Memorial Public Interest Incorporated Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012045","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.semcancer.2019.06.001","type":"journal-article","created":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T20:18:26Z","timestamp":1559938706000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":156,"special_numbering":"C","title":["Antibody therapeutics and immunoregulation in cancer and autoimmune disease"],"prefix":"10.1016","volume":"64","author":[{"given":"Masahiro","family":"Yasunaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2019.06.001_bib0005","article-title":"A potential link between environmental triggers and autoimmunity","volume":"2014","author":"Vojdani","year":"2014","journal-title":"Autoimmune Dis."},{"issue":"1","key":"10.1016\/j.semcancer.2019.06.001_bib0010","first-page":"53","article-title":"Cancer and autoimmunity: harnessing longitudinal cohorts to probe the link, best practice & research","volume":"30","author":"Egiziano","year":"2016","journal-title":"Clin. Rheumatol."},{"issue":"10","key":"10.1016\/j.semcancer.2019.06.001_bib0015","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.autrev.2017.07.022","article-title":"Cancer and autoimmune diseases","volume":"16","author":"Giat","year":"2017","journal-title":"Autoimmun. Rev."},{"issue":"5","key":"10.1016\/j.semcancer.2019.06.001_bib0020","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0092-8674(00)80856-9","article-title":"Regulatory T cells: key controllers of immunologic self-tolerance","volume":"101","author":"Sakaguchi","year":"2000","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.semcancer.2019.06.001_bib0025","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.semcancer.2019.06.001_bib0030","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.semcancer.2019.06.001_bib0035","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1042\/EBC20160017","article-title":"The immune system","volume":"60","author":"Nicholson","year":"2016","journal-title":"Essays Biochem."},{"issue":"3","key":"10.1016\/j.semcancer.2019.06.001_bib0040","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","article-title":"Obstacles posed by the tumor microenvironment to t cell activity: a case for synergistic therapies","volume":"31","author":"Anderson","year":"2017","journal-title":"Cancer Cell"},{"issue":"6024","key":"10.1016\/j.semcancer.2019.06.001_bib0045","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.semcancer.2019.06.001_bib0050","first-page":"75","article-title":"Role of PD-1 in immunity and diseases","volume":"410","author":"Chamoto","year":"2017","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"12","key":"10.1016\/j.semcancer.2019.06.001_bib0055","first-page":"970","article-title":"Immunotherapy of autoimmunity and cancer: the penalty for success, nature reviews","volume":"8","author":"Caspi","year":"2008","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.semcancer.2019.06.001_bib0060","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2011-01-325266","article-title":"Autoimmunity associated with immunotherapy of cancer","volume":"118","author":"Amos","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.semcancer.2019.06.001_bib0065","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich\u2019s magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.semcancer.2019.06.001_bib0070","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nri2761","article-title":"Therapeutic antibodies for autoimmunity and inflammation","volume":"10","author":"Chan","year":"2010","journal-title":"Nat. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.semcancer.2019.06.001_bib0075","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3229","article-title":"Development trends for human monoclonal antibody therapeutics","volume":"9","author":"Nelson","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.semcancer.2019.06.001_bib0080","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2019.06.001_bib0085","first-page":"20","article-title":"Mechanistic considerations for the use of monoclonal antibodies for cancer therapy","volume":"11","author":"Glassman","year":"2014","journal-title":"Cancer Biol. Med."},{"issue":"1","key":"10.1016\/j.semcancer.2019.06.001_bib0090","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4161\/mabs.27333","article-title":"Antibodies to watch in 2014","volume":"6","author":"Reichert","year":"2014","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.semcancer.2019.06.001_bib0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4161\/19420862.2015.988944","article-title":"Antibodies to watch in 2015","volume":"7","author":"Reichert","year":"2015","journal-title":"mAbs"},{"issue":"2","key":"10.1016\/j.semcancer.2019.06.001_bib0100","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/19420862.2015.1125583","article-title":"Antibodies to watch in 2016","volume":"8","author":"Reichert","year":"2016","journal-title":"mAbs"},{"issue":"2","key":"10.1016\/j.semcancer.2019.06.001_bib0105","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/19420862.2016.1269580","article-title":"Antibodies to watch in 2017","volume":"9","author":"Reichert","year":"2017","journal-title":"mAbs"},{"issue":"2","key":"10.1016\/j.semcancer.2019.06.001_bib0110","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/19420862.2018.1415671","article-title":"Antibodies to watch in 2018","volume":"10","author":"Kaplon","year":"2018","journal-title":"mAbs"},{"key":"10.1016\/j.semcancer.2019.06.001_bib0115","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.coph.2018.05.010","article-title":"Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases","volume":"41","author":"Hafeez","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.semcancer.2019.06.001_bib0120","series-title":"Therapeutic Monoclonal Antibodies as Immunomodulators and Anti-cancer Agents: Development, Evidence of Efficacy, Mechanisms of Actions, Adverse Effects","author":"Niehues","year":"2018"},{"issue":"9","key":"10.1016\/j.semcancer.2019.06.001_bib0125","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nbt1137","article-title":"Monoclonal antibody therapy of cancer","volume":"23","author":"Adams","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.semcancer.2019.06.001_bib0130","first-page":"7","article-title":"Improving effector functions of antibodies for cancer treatment: enhancing ADCC and CDC","volume":"3","author":"Natsume","year":"2009","journal-title":"Drug Des. Dev. Therap."},{"issue":"6","key":"10.1016\/j.semcancer.2019.06.001_bib0135","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.cell.2012.02.034","article-title":"Antibody-based immunotherapy of cancer","volume":"148","author":"Weiner","year":"2012","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.semcancer.2019.06.001_bib0140","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nbt.3212","article-title":"Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index","volume":"33","author":"Lyon","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.semcancer.2019.06.001_bib0145","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines4030014","article-title":"Antibody-drug conjugates for cancer therapy","volume":"4","author":"Parslow","year":"2016","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.semcancer.2019.06.001_bib0150","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/bjc.2015.435","article-title":"Antibody-drug conjugates--an emerging class of cancer treatment","volume":"114","author":"Diamantis","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.semcancer.2019.06.001_bib0155","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s12325-017-0519-6","article-title":"Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review","volume":"34","author":"Lambert","year":"2017","journal-title":"Adv. Ther."},{"key":"10.1016\/j.semcancer.2019.06.001_bib0160","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ddtec.2018.09.003","article-title":"Bispecifics and antibody-drug conjugates: a positive synergy","volume":"30","author":"Maruani","year":"2018","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.semcancer.2019.06.001_bib0165","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2147\/DDDT.S151282","article-title":"Bispecific antibodies: design, therapy, perspectives","volume":"12","author":"Sedykh","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"issue":"7","key":"10.1016\/j.semcancer.2019.06.001_bib0170","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-17-0749","article-title":"A HER2-Targeting antibody-drug conjugate, Trastuzumab Deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model","volume":"17","author":"Iwata","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.semcancer.2019.06.001_bib0175","article-title":"Development of antibody-drug conjugates using DDS and molecular imaging","volume":"4","author":"Yasunaga","year":"2017","journal-title":"Bioengineering (Basel, Switzerland)"},{"issue":"2","key":"10.1016\/j.semcancer.2019.06.001_bib0180","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3934\/medsci.2018.2.162","article-title":"Mass spectrometry imaging for early discovery and development of cancer drugs","volume":"5","author":"Y. M","year":"2018","journal-title":"AIMS Med. Sci."},{"issue":"20","key":"10.1016\/j.semcancer.2019.06.001_bib0185","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.3748\/wjg.v22.i20.4794","article-title":"Inflammatory bowel disease and cancer: the role of inflammation, immunosuppression, and cancer treatment","volume":"22","author":"Axelrad","year":"2016","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.semcancer.2019.06.001_bib0190","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z","article-title":"Cancer risk in patients with inflammatory bowel disease: a population-based study","volume":"91","author":"Bernstein","year":"2001","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.semcancer.2019.06.001_bib0195","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1136\/gut.52.8.1211","article-title":"Small bowel neoplasia in coeliac disease","volume":"52","author":"Rampertab","year":"2003","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.semcancer.2019.06.001_bib0200","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0002-9343(03)00302-4","article-title":"Risk of malignancy in patients with celiac disease","volume":"115","author":"Green","year":"2003","journal-title":"Am. J. Med."},{"issue":"6","key":"10.1016\/j.semcancer.2019.06.001_bib0205","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.semcancer.2019.06.001_bib0210","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.critrevonc.2008.07.021","article-title":"Infections and cancer: established associations and new hypotheses","volume":"70","author":"de Martel","year":"2009","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"6917","key":"10.1016\/j.semcancer.2019.06.001_bib0215","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.semcancer.2019.06.001_bib0220","doi-asserted-by":"crossref","first-page":"F23","DOI":"10.1084\/jem.193.6.F23","article-title":"Inflammatory cells and cancer: think different!","volume":"193","author":"Coussens","year":"2001","journal-title":"J. Exp. Med."},{"issue":"7042","key":"10.1016\/j.semcancer.2019.06.001_bib0225","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nature03724","article-title":"Cellular and genetic mechanisms of self tolerance and autoimmunity","volume":"435","author":"Goodnow","year":"2005","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.semcancer.2019.06.001_bib0230","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1365-2796.2007.01852.x","article-title":"Obesity-induced inflammation: a metabolic dialogue in the language of inflammation","volume":"262","author":"Ferrante","year":"2007","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.semcancer.2019.06.001_bib0235","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fonc.2017.00216","article-title":"Obesity and cancer metabolism: a perspective on interacting tumor-intrinsic and extrinsic factors","volume":"7","author":"Doerstling","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.semcancer.2019.06.001_bib0240","first-page":"98","article-title":"Chronic inflammation in cancer development","volume":"2","author":"Multhoff","year":"2011","journal-title":"Front. Immunol."},{"issue":"26","key":"10.1016\/j.semcancer.2019.06.001_bib0245","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.2174\/138161212802083707","article-title":"Molecular link mechanisms between inflammation and cancer","volume":"18","author":"Vendramini-Costa","year":"2012","journal-title":"Curr. Pharm. Des."},{"issue":"20","key":"10.1016\/j.semcancer.2019.06.001_bib0250","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1001\/archinte.165.20.2337","article-title":"The risk of lymphoma development in autoimmune diseases: a meta-analysis","volume":"165","author":"Zintzaras","year":"2005","journal-title":"Arch. Intern. Med."},{"issue":"1","key":"10.1016\/j.semcancer.2019.06.001_bib0255","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/jnci\/djj004","article-title":"Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype","volume":"98","author":"Smedby","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/j.semcancer.2019.06.001_bib0260","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.coi.2011.10.007","article-title":"B cells and autoimmunity","volume":"23","author":"Pillai","year":"2011","journal-title":"Curr. Opin. Immunol."},{"issue":"4","key":"10.1016\/j.semcancer.2019.06.001_bib0265","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0002-9440(10)63481-5","article-title":"T-cell-mediated autoimmunity: novel techniques to characterize autoreactive T-cell receptors","volume":"163","author":"Dornmair","year":"2003","journal-title":"Am. J. Pathol."},{"issue":"5594","key":"10.1016\/j.semcancer.2019.06.001_bib0270","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science (New York, N.Y.)"},{"issue":"5517","key":"10.1016\/j.semcancer.2019.06.001_bib0275","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.semcancer.2019.06.001_bib0280","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10928-014-9367-z","article-title":"Review on modeling anti-antibody responses to monoclonal antibodies","volume":"41","author":"Gomez-Mantilla","year":"2014","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"10","key":"10.1016\/j.semcancer.2019.06.001_bib0285","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","article-title":"Humanization of an anti-p185HER2 antibody for human cancer therapy","volume":"89","author":"Carter","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.semcancer.2019.06.001_bib0290","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nrd984","article-title":"Therapeutic antibodies for human diseases at the dawn of the twenty-first century","volume":"2","author":"Brekke","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.semcancer.2019.06.001_bib0295","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions","volume":"2","author":"Harding","year":"2010","journal-title":"mAbs"},{"issue":"12 Pt 1","key":"10.1016\/j.semcancer.2019.06.001_bib0300","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.semcancer.2019.06.001_bib0305","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1349-7006.1988.tb01563.x","article-title":"Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue","volume":"79","author":"Matsumura","year":"1988","journal-title":"Jpn. J. Cancer Res."},{"issue":"12","key":"10.1016\/j.semcancer.2019.06.001_bib0310","first-page":"3229","article-title":"Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood","volume":"51","author":"Yokoyama","year":"1991","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.semcancer.2019.06.001_bib0315","first-page":"231","article-title":"Long-circulating liposomes","volume":"11","author":"Oku","year":"1994","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"issue":"12","key":"10.1016\/j.semcancer.2019.06.001_bib0320","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat. Nanotechnol."},{"issue":"3","key":"10.1016\/j.semcancer.2019.06.001_bib0325","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.addr.2010.03.011","article-title":"Tumor delivery of macromolecular drugs based on the EPR effect","volume":"63","author":"Torchilin","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.semcancer.2019.06.001_bib0330","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.addr.2010.09.003","article-title":"Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects","volume":"63","author":"Maruyama","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.semcancer.2019.06.001_bib0335","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.addr.2010.09.001","article-title":"A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma","volume":"63","author":"Hatakeyama","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7","key":"10.1016\/j.semcancer.2019.06.001_bib0340","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/cas.12960","article-title":"Development of polymeric micelles for targeting intractable cancers","volume":"107","author":"Nishiyama","year":"2016","journal-title":"Cancer Sci."},{"issue":"9-10","key":"10.1016\/j.semcancer.2019.06.001_bib0345","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/1061186X.2017.1358729","article-title":"Polymer therapeutics at a crossroads? Finding the path for improved translation in the twenty-first century","volume":"25","author":"Duncan","year":"2017","journal-title":"J. Drug Target."},{"key":"10.1016\/j.semcancer.2019.06.001_bib0350","article-title":"Janeway\u2019s immunobiology","author":"Murphy","year":"2012","journal-title":"Garland Sci. N. Y."},{"issue":"1","key":"10.1016\/j.semcancer.2019.06.001_bib0355","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4049\/jimmunol.180.1.361","article-title":"Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice","volume":"180","author":"DiLillo","year":"2008","journal-title":"J. Immunol. (Baltim. Md.: 1950)"},{"key":"10.1016\/j.semcancer.2019.06.001_bib0360","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3389\/fimmu.2017.01245","article-title":"Therapeutic antibodies: What have we learnt from targeting CD20 and Where are we going?","volume":"8","author":"Marshall","year":"2017","journal-title":"Front. Immunol."},{"issue":"47","key":"10.1016\/j.semcancer.2019.06.001_bib0365","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.semcancer.2019.06.001_bib0370","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1038\/bcj.2015.115","article-title":"Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcgammaRIIIa polymorphism. A study of FCGCLL\/WM and GOELAMS groups","volume":"6","author":"Gagez","year":"2016","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.semcancer.2019.06.001_bib0375","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.2008.001628","article-title":"Anti-CD20 monoclonal antibodies: historical and future perspectives","volume":"95","author":"Lim","year":"2010","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.semcancer.2019.06.001_bib0380","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/sj.leu.2402226","article-title":"CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells","volume":"15","author":"Selenko","year":"2001","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.semcancer.2019.06.001_bib0385","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4161\/mabs.2.1.10789","article-title":"Evolution of anti-CD20 monoclonal antibody therapeutics in oncology","volume":"2","author":"Oflazoglu","year":"2010","journal-title":"mAbs"},{"issue":"10","key":"10.1016\/j.semcancer.2019.06.001_bib0390","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.semcancer.2019.06.001_bib0395","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/14712598.2018.1508444","article-title":"The latest developments with anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia","volume":"18","author":"Evers","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"issue":"3","key":"10.1016\/j.semcancer.2019.06.001_bib0400","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/cei.12197","article-title":"Monoclonal antibodies in treatment of multiple sclerosis","volume":"175","author":"Rommer","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.semcancer.2019.06.001_bib0405","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418773025","article-title":"Ocrelizumab: a new milestone in multiple sclerosis therapy","volume":"11","author":"Mulero","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"4","key":"10.1016\/j.semcancer.2019.06.001_bib0410","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000342164","article-title":"Tumor-associated antigens in breast cancer","volume":"7","author":"Criscitiello","year":"2012","journal-title":"Breast Care (Basel, Switzerland)"},{"issue":"4","key":"10.1016\/j.semcancer.2019.06.001_bib0415","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10040168","article-title":"Concepts and challenges of biosimilars in breast cancer: the emergence of Trastuzumab Biosimilars","volume":"10","author":"Uifalean","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.semcancer.2019.06.001_bib0420","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejca.2018.01.072","article-title":"A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: final safety, immunogenicity and survival results","volume":"93","author":"Pivot","year":"2018","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.semcancer.2019.06.001_bib0425","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1080\/19420862.2018.1486946","article-title":"Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody","volume":"10","author":"Huang","year":"2018","journal-title":"mAbs"},{"issue":"11","key":"10.1016\/j.semcancer.2019.06.001_bib0430","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1021\/acs.bioconjchem.8b00668","article-title":"Site-specific conjugation of auristatins onto engineered scFv using second generation maleimide to target HER2-positive breast cancer in vitro","volume":"29","author":"Aubrey","year":"2018","journal-title":"Bioconjug. Chem."},{"issue":"1","key":"10.1016\/j.semcancer.2019.06.001_bib0435","first-page":"50","article-title":"Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics","volume":"24","author":"Runcie","year":"2018","journal-title":"Mol. Med. (Cambridge, Mass.)"},{"issue":"20","key":"10.1016\/j.semcancer.2019.06.001_bib0440","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the treatment of colorectal cancer","volume":"357","author":"Jonker","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.semcancer.2019.06.001_bib0445","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.21873\/anticanres.10985","article-title":"The role of cetuximab in the induction of anticancer immune response in colorectal cancer treatment","volume":"36","author":"Holubec","year":"2016","journal-title":"Anticancer Res."},{"issue":"3","key":"10.1016\/j.semcancer.2019.06.001_bib0450","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1159\/000485404","article-title":"Cetuximab enhanced the cytotoxic activity of immune cells during treatment of colorectal cancer","volume":"44","author":"Wang","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"issue":"21","key":"10.1016\/j.semcancer.2019.06.001_bib0455","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.1158\/1078-0432.CCR-15-2971","article-title":"Anti-EGFR targeted monoclonal antibody isotype influences antitumor cellular immunity in head and neck cancer patients","volume":"22","author":"Trivedi","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.semcancer.2019.06.001_bib0460","first-page":"7","article-title":"Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer","volume":"18","author":"Krawczyk","year":"2014","journal-title":"Contemp. Oncol. (Poznan, Poland)"},{"key":"10.1016\/j.semcancer.2019.06.001_bib0465","article-title":"Immune effector functions of human IgG2 antibodies against EGFR","author":"Rosner","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"10.1016\/j.semcancer.2019.06.001_bib0470","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1634\/theoncologist.2009-0317","article-title":"Bevacizumab","volume":"15","author":"Kazazi-Hyseni","year":"2010","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.semcancer.2019.06.001_bib0475","doi-asserted-by":"crossref","first-page":"659","DOI":"10.7150\/ijms.24453","article-title":"New trends in the therapeutic approach to metastatic colorectal Cancer","volume":"15","author":"Sanchez-Gundin","year":"2018","journal-title":"Int. J. Med. Sci."},{"issue":"9911","key":"10.1016\/j.semcancer.2019.06.001_bib0480","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet (London, England)"},{"issue":"9","key":"10.1016\/j.semcancer.2019.06.001_bib0485","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.semcancer.2019.06.001_bib0490","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.semcancer.2019.06.001_bib0495","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrd4591","article-title":"Combination cancer immunotherapy and new immunomodulatory targets","volume":"14","author":"Mahoney","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.semcancer.2019.06.001_bib0500","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.semcancer.2019.06.001_bib0505","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12929-017-0329-9","article-title":"Cancer immunotherapies targeting the PD-1 signaling pathway","volume":"24","author":"Iwai","year":"2017","journal-title":"J. Biomed. Sci."},{"issue":"3","key":"10.1016\/j.semcancer.2019.06.001_bib0510","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.semcancer.2019.06.001_bib0515","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.semcancer.2019.06.001_bib0520","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2217\/imt-2016-0049","article-title":"Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside","volume":"8","author":"Kuhn","year":"2016","journal-title":"Immunotherapy"},{"issue":"3","key":"10.1016\/j.semcancer.2019.06.001_bib0525","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3390\/toxins6030869","article-title":"Monoclonal antibody therapy and renal transplantation: focus on adverse effects","volume":"6","author":"Zaza","year":"2014","journal-title":"Toxins"},{"issue":"5","key":"10.1016\/j.semcancer.2019.06.001_bib0530","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1212\/NXI.0000000000000481","article-title":"GFAPalpha IgG-associated encephalitis upon daclizumab treatment of MS","volume":"5","author":"Luessi","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"7","key":"10.1016\/j.semcancer.2019.06.001_bib0535","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.4049\/jimmunol.1502570","article-title":"Human CD56bright NK cells: an update","volume":"196","author":"Michel","year":"2016","journal-title":"J. Immunol. (Baltim. Md. : 1950)"},{"issue":"1","key":"10.1016\/j.semcancer.2019.06.001_bib0540","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1756285615615257","article-title":"Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis","volume":"9","author":"Sellebjerg","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"1","key":"10.1016\/j.semcancer.2019.06.001_bib0545","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/intimm\/dxu096","article-title":"Therapeutic uses of anti-alpha4-integrin (anti-VLA-4) antibodies in multiple sclerosis","volume":"27","author":"Schwab","year":"2015","journal-title":"Int. Immunol."},{"issue":"7","key":"10.1016\/j.semcancer.2019.06.001_bib0550","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/cam4.1098","article-title":"Melanoma complicating treatment with natalizumab for multiple sclerosis: a report from the Southern Network on Adverse Reactions (SONAR)","volume":"6","author":"Sabol","year":"2017","journal-title":"Cancer Med."},{"issue":"7","key":"10.1016\/j.semcancer.2019.06.001_bib0555","doi-asserted-by":"crossref","first-page":"16414","DOI":"10.3390\/ijms160716414","article-title":"Alemtuzumab in multiple sclerosis: mechanism of action and beyond","volume":"16","author":"Ruck","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2019.06.001_bib0560","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2147\/TCRM.S143509","article-title":"Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program","volume":"13","author":"Havrdova","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.semcancer.2019.06.001_bib0565","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2147\/TCRM.S134398","article-title":"Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis","volume":"13","author":"Guarnera","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"issue":"1","key":"10.1016\/j.semcancer.2019.06.001_bib0570","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s13317-017-0100-y","article-title":"Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment","volume":"8","author":"Du","year":"2017","journal-title":"Auto Immun. Highlights"},{"issue":"4","key":"10.1016\/j.semcancer.2019.06.001_bib0575","doi-asserted-by":"crossref","first-page":"820","DOI":"10.4161\/mabs.29105","article-title":"Rituximab: how approval history is reflected by a corresponding patent filing strategy","volume":"6","author":"Storz","year":"2014","journal-title":"mAbs"},{"issue":"2","key":"10.1016\/j.semcancer.2019.06.001_bib0580","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/19420862.2015.1011450","article-title":"Macrophages are critical effectors of antibody therapies for cancer","volume":"7","author":"Weiskopf","year":"2015","journal-title":"mAbs"},{"key":"10.1016\/j.semcancer.2019.06.001_bib0585","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3389\/fphar.2017.00460","article-title":"Drugs for autoimmune inflammatory diseases: from small molecule compounds to Anti-TNF biologics","volume":"8","author":"Li","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"19","key":"10.1016\/j.semcancer.2019.06.001_bib0590","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"Jama"},{"issue":"8","key":"10.1016\/j.semcancer.2019.06.001_bib0595","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn\u2019s disease: a meta-analysis","volume":"7","author":"Siegel","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.semcancer.2019.06.001_bib0600","first-page":"h2809","article-title":"Association between tumour necrosis factor-alpha inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study","volume":"350","author":"Nyboe Andersen","year":"2015","journal-title":"BMJ (Clinical Research ed.)"},{"issue":"19","key":"10.1016\/j.semcancer.2019.06.001_bib0605","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.3748\/wjg.v20.i19.5912","article-title":"TNF inhibitors to treat ulcerative colitis in a metastatic breast cancer patient: a case report and literature review","volume":"20","author":"Ben Musa","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.semcancer.2019.06.001_bib0610","first-page":"281","article-title":"Cutaneous side effects of TNF-alpha inhibitors","volume":"15","author":"Lindhaus","year":"2017","journal-title":"J. Dermatol. Ges."},{"issue":"2","key":"10.1016\/j.semcancer.2019.06.001_bib0615","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jaad.2016.07.039","article-title":"Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: prospective meta-analysis of Psonet registries","volume":"76","author":"Garcia-Doval","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.semcancer.2019.06.001_bib0620","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000213","article-title":"Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab","volume":"2","author":"Rubbert-Roth","year":"2016","journal-title":"RMD Open"},{"issue":"9","key":"10.1016\/j.semcancer.2019.06.001_bib0625","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/nbt1141","article-title":"Arming antibodies: prospects and challenges for immunoconjugates","volume":"23","author":"Wu","year":"2005","journal-title":"Nat. Biotechnol."},{"issue":"13","key":"10.1016\/j.semcancer.2019.06.001_bib0630","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1158\/1078-0432.CCR-06-0059","article-title":"Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent","volume":"12","author":"Asano","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"5891","key":"10.1016\/j.semcancer.2019.06.001_bib0635","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science (New York, N.Y.)"},{"issue":"7","key":"10.1016\/j.semcancer.2019.06.001_bib0640","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/j.1349-7006.2011.01954.x","article-title":"New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots","volume":"102","author":"Yasunaga","year":"2011","journal-title":"Cancer Sci."},{"issue":"7","key":"10.1016\/j.semcancer.2019.06.001_bib0645","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"30","author":"Senter","year":"2012","journal-title":"Nat. Biotechnol."},{"issue":"5","key":"10.1016\/j.semcancer.2019.06.001_bib0650","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1053\/j.seminoncol.2014.08.001","article-title":"The next generation of antibody drug conjugates","volume":"41","author":"Mack","year":"2014","journal-title":"Semin. Oncol."},{"issue":"Suppl. 3","key":"10.1016\/j.semcancer.2019.06.001_bib0655","first-page":"S21","article-title":"Clinical pharmacology of bispecific antibody constructs","volume":"55","author":"Rathi","year":"2015","journal-title":"J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.semcancer.2019.06.001_bib0660","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody-drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2019.06.001_bib0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2017.05.011","article-title":"Advances in antibody-drug conjugates: a new era of targeted cancer therapy","author":"Sau","year":"2017","journal-title":"Drug Discov. Today"},{"issue":"410","key":"10.1016\/j.semcancer.2019.06.001_bib0670","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal4291","article-title":"An anti-glypican 3\/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors","volume":"9","author":"Ishiguro","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.semcancer.2019.06.001_bib0675","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1002\/ijc.30870","article-title":"DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance, International journal of cancer","volume":"141","author":"Takegawa","year":"2017","journal-title":"Int. J. Cancer Suppl."},{"issue":"3","key":"10.1016\/j.semcancer.2019.06.001_bib0680","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00277-014-2218-6","article-title":"Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia","volume":"94","author":"Loke","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.semcancer.2019.06.001_bib0685","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.leukres.2018.09.001","article-title":"Recently approved therapies in acute myeloid leukemia: a complex treatment landscape","volume":"73","author":"Talati","year":"2018","journal-title":"Leuk. Res."},{"issue":"8","key":"10.1016\/j.semcancer.2019.06.001_bib0690","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.semcancer.2019.06.001_bib0695","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1186\/s12885-018-5026-x","article-title":"Inotuzumab ozogamicin is effective in relapsed\/refractory extramedullary B acute lymphoblastic leukemia","volume":"18","author":"Bertamini","year":"2018","journal-title":"BMC Cancer"},{"issue":"18","key":"10.1016\/j.semcancer.2019.06.001_bib0700","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.semcancer.2019.06.001_bib0705","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.semcancer.2019.06.001_bib0710","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.semcancer.2019.06.001_bib0715","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4251\/wjgo.v10.i7.159","article-title":"HER2 inhibition in gastro-oesophageal cancer: a review drawing on lessons learned from breast cancer","volume":"10","author":"Lote","year":"2018","journal-title":"World J. Gastrointest. Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2019.06.001_bib0720","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1517\/14712598.2016.1161753","article-title":"Antibody-drug conjugates for non-oncological indications","volume":"16","author":"Liu","year":"2016","journal-title":"Expert Opin. Biol. Ther."},{"issue":"9","key":"10.1016\/j.semcancer.2019.06.001_bib0725","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1021\/jacs.5b00620","article-title":"An immunosuppressive antibody-drug conjugate","volume":"137","author":"Wang","year":"2015","journal-title":"J. Am. Chem. Soc."},{"issue":"2 Pt A","key":"10.1016\/j.semcancer.2019.06.001_bib0730","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2015.01.003","article-title":"Alternative molecular formats and therapeutic applications for bispecific antibodies","volume":"67","author":"Spiess","year":"2015","journal-title":"Mol. Immunol."},{"issue":"2","key":"10.1016\/j.semcancer.2019.06.001_bib0735","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.semcancer.2019.06.001_bib0740","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2515135518763280","article-title":"Bispecific antibodies in cancer immunotherapy","volume":"6","author":"Dahlen","year":"2018","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"10.1016\/j.semcancer.2019.06.001_bib0745","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.coi.2016.02.006","article-title":"Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection","volume":"40","author":"Zhukovsky","year":"2016","journal-title":"Curr. Opin. Immunol."},{"issue":"11","key":"10.1016\/j.semcancer.2019.06.001_bib0750","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1158\/2326-6066.CIR-14-0161","article-title":"The immunological synapse","volume":"2","author":"Dustin","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"3","key":"10.1016\/j.semcancer.2019.06.001_bib0755","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines6030054","article-title":"Early investigations and recent advances in intraperitoneal immunotherapy for peritoneal metastasis","volume":"6","author":"Thadi","year":"2018","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.semcancer.2019.06.001_bib0760","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/cts.12459","article-title":"Clinical pharmacology and translational aspects of bispecific antibodies","volume":"10","author":"Trivedi","year":"2017","journal-title":"Clin. Transl. Sci."},{"issue":"36","key":"10.1016\/j.semcancer.2019.06.001_bib0765","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2019.06.001_bib0770","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fonc.2017.00064","article-title":"Advancing Cancer therapy with present and emerging immuno-oncology approaches","volume":"7","author":"Kamta","year":"2017","journal-title":"Front. Oncol."},{"issue":"26","key":"10.1016\/j.semcancer.2019.06.001_bib0775","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.semcancer.2019.06.001_bib0780","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2217\/imt-2016-0020","article-title":"Immunotherapeutic implications of IL-6 blockade for cytokine storm","volume":"8","author":"Tanaka","year":"2016","journal-title":"Immunotherapy"},{"issue":"15","key":"10.1016\/j.semcancer.2019.06.001_bib0785","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1096\/fasebj.8.15.8001742","article-title":"Idiotypic induction of autoimmunity: a new aspect of the idiotypic network","volume":"8","author":"Shoenfeld","year":"1994","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.semcancer.2019.06.001_bib0790","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10875-007-9088-9","article-title":"Intravenous immunoglobulin: an update on the clinical use and mechanisms of action","volume":"27","author":"Negi","year":"2007","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.semcancer.2019.06.001_bib0795","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fimmu.2014.00086","article-title":"Self-tolerance in a minimal model of the idiotypic network","volume":"5","author":"Schulz","year":"2014","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.semcancer.2019.06.001_bib0800","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/art.40580","article-title":"ABT-122, a bispecific dual variable domain immunoglobulin targeting tumor necrosis factor and Interleukin-17A, in patients with rheumatoid arthritis with an inadequate response to methotrexate: a randomized, double-blind study","volume":"70","author":"Genovese","year":"2018","journal-title":"Arthr. Rheumatol. (Hoboken, N.J.)"},{"issue":"1","key":"10.1016\/j.semcancer.2019.06.001_bib0805","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/19420862.2015.1093266","article-title":"Discovery and characterization of COVA322, a clinical-stage bispecific TNF\/IL-17A inhibitor for the treatment of inflammatory diseases","volume":"8","author":"Silacci","year":"2016","journal-title":"mAbs"},{"issue":"17","key":"10.1016\/j.semcancer.2019.06.001_bib0810","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2019.06.001_bib0815","series-title":"Endotext","article-title":"Glucocorticoid therapy and adrenal suppression","author":"Nicolaides","year":"2000"},{"issue":"11","key":"10.1016\/j.semcancer.2019.06.001_bib0820","first-page":"670","article-title":"Glucocorticoid sensitivity in health and disease, Nature reviews","volume":"9","author":"Quax","year":"2013","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.semcancer.2019.06.001_bib0825","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5493\/wjem.v3.i2.21","article-title":"Steroid resistance in leukemia","volume":"3","author":"Shah","year":"2013","journal-title":"World J. Exp. Med."},{"issue":"12","key":"10.1016\/j.semcancer.2019.06.001_bib0830","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002200","article-title":"IL-7 receptor mutations and steroid resistance in pediatric t cell acute lymphoblastic leukemia: a genome sequencing study","volume":"13","author":"Li","year":"2016","journal-title":"PLoS Med."},{"issue":"11","key":"10.1016\/j.semcancer.2019.06.001_bib0835","first-page":"867","article-title":"Homing and cellular traffic in lymph nodes, nature reviews","volume":"3","author":"von Andrian","year":"2003","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.semcancer.2019.06.001_bib0840","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2183\/pjab.93.012","article-title":"The molecular cues regulating immune cell trafficking","volume":"93","author":"Takeda","year":"2017","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"issue":"3","key":"10.1016\/j.semcancer.2019.06.001_bib0845","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1182\/blood.V78.3.564.564","article-title":"Engagement of interleukin-7 receptor stimulates tyrosine phosphorylation, phosphoinositide turnover, and clonal proliferation of human T-lineage acute lymphoblastic leukemia cells","volume":"78","author":"Dibirdik","year":"1991","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.semcancer.2019.06.001_bib0850","doi-asserted-by":"crossref","first-page":"12083","DOI":"10.1073\/pnas.89.24.12083","article-title":"Interleukin 7 receptor functions by recruiting the tyrosine kinase p59fyn through a segment of its cytoplasmic tail","volume":"89","author":"Venkitaraman","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.semcancer.2019.06.001_bib0855","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1172\/JCI116736","article-title":"Activation of phosphatidylinositol-3 kinase by ligation of the interleukin-7 receptor on human thymocytes","volume":"92","author":"Dadi","year":"1993","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.semcancer.2019.06.001_bib0860","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/1044-5323(95)90046-2","article-title":"Making the in-vitro model closer to actual B lymphopoiesis in the bone marrow","volume":"7","author":"Yasunaga","year":"1995","journal-title":"Semin. Immunol."},{"issue":"2","key":"10.1016\/j.semcancer.2019.06.001_bib0865","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1084\/jem.182.2.315","article-title":"Cell cycle control of c-kit+IL-7R+ B precursor cells by two distinct signals derived from IL-7 receptor and c-kit in a fully defined medium","volume":"182","author":"Yasunaga","year":"1995","journal-title":"J. Exp. Med."},{"issue":"1-2","key":"10.1016\/j.semcancer.2019.06.001_bib0870","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1083\/jcb.132.1.91","article-title":"Involvement of Fyn tyrosine kinase in progression of cytokinesis of B lymphocyte progenitor","volume":"132","author":"Yasunaga","year":"1996","journal-title":"J. Cell Biol."},{"issue":"5","key":"10.1016\/j.semcancer.2019.06.001_bib0875","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0092-8674(00)80453-5","article-title":"Identification of clonogenic common lymphoid progenitors in mouse bone marrow","volume":"91","author":"Kondo","year":"1997","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.semcancer.2019.06.001_bib0880","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0092-8674(00)80291-3","article-title":"Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor-deficient mice","volume":"89","author":"Akashi","year":"1997","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.semcancer.2019.06.001_bib0885","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1359-6101(98)00025-2","article-title":"Interleukin-7: physiological roles and mechanisms of action","volume":"10","author":"Hofmeister","year":"1999","journal-title":"Cytokine Growth Factor Rev."},{"issue":"3","key":"10.1016\/j.semcancer.2019.06.001_bib0890","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.smim.2012.04.010","article-title":"IL-7 signaling and CD127 receptor regulation in the control of T cell homeostasis","volume":"24","author":"Carrette","year":"2012","journal-title":"Semin. Immunol."},{"issue":"4","key":"10.1016\/j.semcancer.2019.06.001_bib0895","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3892\/ijo.2014.2290","article-title":"p27KIP1 is involved in ERK1\/2-mediated MMP-9 expression via the activation of NF-kappaB binding in the IL-7-induced migration and invasion of 5637 cells","volume":"44","author":"Park","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.semcancer.2019.06.001_bib0900","article-title":"IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: an update","author":"Oliveira","year":"2018","journal-title":"Adv. Biol. Regul."},{"issue":"32","key":"10.1016\/j.semcancer.2019.06.001_bib0905","doi-asserted-by":"crossref","first-page":"22605","DOI":"10.18632\/oncotarget.25194","article-title":"Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Ralpha mutations","volume":"9","author":"Senkevitch","year":"2018","journal-title":"Oncotarget"},{"issue":"17","key":"10.1016\/j.semcancer.2019.06.001_bib0910","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/bloodadvances.2018021063","article-title":"STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells","volume":"2","author":"Ribeiro","year":"2018","journal-title":"Blood Adv."},{"issue":"5987","key":"10.1016\/j.semcancer.2019.06.001_bib0915","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1126\/science.1188995","article-title":"An essential developmental checkpoint for production of the T cell lineage","volume":"329","author":"Ikawa","year":"2010","journal-title":"Science (New York, N.Y.)"},{"issue":"5","key":"10.1016\/j.semcancer.2019.06.001_bib0920","first-page":"2212","article-title":"Positive effects of glucocorticoids on T cell function by up-regulation of IL-7 receptor alpha","volume":"168","author":"Franchimont","year":"2002","journal-title":"J. Immunol. Baltim. Md.: 1950"},{"issue":"12","key":"10.1016\/j.semcancer.2019.06.001_bib0925","first-page":"7800","article-title":"Transcriptional regulation of the mouse IL-7 receptor alpha promoter by glucocorticoid receptor","volume":"174","author":"Lee","year":"2005","journal-title":"J. Immunol. Baltim. Md.: 1950"},{"issue":"1","key":"10.1016\/j.semcancer.2019.06.001_bib0930","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.imlet.2007.04.012","article-title":"Induction of the IL-7 receptor alpha chain in mouse peripheral B cells by glucocorticoids","volume":"111","author":"Shibata","year":"2007","journal-title":"Immunol. Lett."},{"issue":"2","key":"10.1016\/j.semcancer.2019.06.001_bib0935","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.immuni.2018.01.004","article-title":"Glucocorticoids drive diurnal oscillations in t cell distribution and responses by inducing Interleukin-7 receptor and CXCR4","volume":"48","author":"Shimba","year":"2018","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.semcancer.2019.06.001_bib0940","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/ng.924","article-title":"Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia","volume":"43","author":"Zenatti","year":"2011","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.semcancer.2019.06.001_bib0945","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.smim.2012.02.007","article-title":"The human IL-7 receptor gene: deletions, polymorphisms and mutations","volume":"24","author":"Mazzucchelli","year":"2012","journal-title":"Semin. Immunol."},{"issue":"13","key":"10.1016\/j.semcancer.2019.06.001_bib0950","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2013-01-478073","article-title":"Interleukin-7 is produced by afferent lymphatic vessels and supports lymphatic drainage","volume":"122","author":"Iolyeva","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.semcancer.2019.06.001_bib0955","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/intimm\/dxt012","article-title":"IL-7 production in murine lymphatic endothelial cells and induction in the setting of peripheral lymphopenia","volume":"25","author":"Miller","year":"2013","journal-title":"Int. Immunol."},{"issue":"2","key":"10.1016\/j.semcancer.2019.06.001_bib0960","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.immuni.2004.07.016","article-title":"Suppression of IL7Ralpha transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival","volume":"21","author":"Park","year":"2004","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.semcancer.2019.06.001_bib0965","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/ni.1840","article-title":"Signaling by intrathymic cytokines, not T cell antigen receptors, specifies CD8 lineage choice and promotes the differentiation of cytotoxic-lineage T cells","volume":"11","author":"Park","year":"2010","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.semcancer.2019.06.001_bib0970","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/ni.2494","article-title":"IL-7 signaling must be intermittent, not continuous, during CD8(+) T cell homeostasis to promote cell survival instead of cell death","volume":"14","author":"Kimura","year":"2013","journal-title":"Nat. Immunol."},{"issue":"10","key":"10.1016\/j.semcancer.2019.06.001_bib0975","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1084\/jem.20120905","article-title":"Autoreactive T cells bypass negative selection and respond to self-antigen stimulation during infection","volume":"209","author":"Enouz","year":"2012","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.semcancer.2019.06.001_bib0980","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nri3667","article-title":"Positive and negative selection of the T cell repertoire: what thymocytes see (and don\u2019t see)","volume":"14","author":"Klein","year":"2014","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.semcancer.2019.06.001_bib0985","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41590-018-0128-9","article-title":"Thymic tolerance as a key brake on autoimmunity","volume":"19","author":"Cheng","year":"2018","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.semcancer.2019.06.001_bib0990","doi-asserted-by":"crossref","first-page":"10735","DOI":"10.1038\/s41598-017-11255-4","article-title":"Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease","volume":"7","author":"Yasunaga","year":"2017","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.semcancer.2019.06.001_bib0995","first-page":"701","article-title":"Expression of B-cell antigens by Hodgkin\u2019s and Reed-Sternberg cells","volume":"139","author":"Schmid","year":"1991","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.semcancer.2019.06.001_bib1000","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1182\/blood.V82.1.247.bloodjournal821247","article-title":"Characterization of posttransplant lymphomas that express T-cell-associated markers: immunophenotypes, molecular genetics, cytogenetics, and heterotransplantation in severe combined immunodeficient mice","volume":"82","author":"Waller","year":"1993","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.semcancer.2019.06.001_bib1005","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S0022-5347(17)43590-7","article-title":"Total and specific immunoglobulin response to acute and chronic urinary tract infections in a rat model","volume":"138","author":"Davis","year":"1987","journal-title":"J. Urol."},{"issue":"4","key":"10.1016\/j.semcancer.2019.06.001_bib1010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1023\/A:1020563913045","article-title":"New insights into the biology of the acute phase response","volume":"19","author":"Suffredini","year":"1999","journal-title":"J. Clin. Immunol."}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X18301871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X18301871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:42:34Z","timestamp":1760917354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X18301871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":202,"alternative-id":["S1044579X18301871"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2019.06.001","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody therapeutics and immunoregulation in cancer and autoimmune disease","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2019.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}